Art

J-GLOBAL ID：202002256376248994   Reference number：20A0444529

Antitumor activity of the PD-1/PD-L1 binding inhibitor BMS-202 in the humanized MHC-double knockout NOG mouse

ヒト化MHCダブルノックアウトNOGマウスにおけるPD-1/PD-L1結合阻害剤BMS-202の抗腫瘍活性

Author (12)： ASHIZAWA Tadashi (Immunotherapy Division, Shizuoka Cancer Center Research Institute) ,  IIZUKA Akira (Immunotherapy Division, Shizuoka Cancer Center Research Institute) ,  TANAKA Emiko (Immunotherapy Division, Shizuoka Cancer Center Research Institute) ,  KONDOU Ryota (Immunotherapy Division, Shizuoka Cancer Center Research Institute) ,  MIYATA Haruo (Immunotherapy Division, Shizuoka Cancer Center Research Institute) ,  MAEDA Chie (Immunotherapy Division, Shizuoka Cancer Center Research Institute) ,  SUGINO Takashi (Division of Pathology, Shizuoka Cancer Center Hospital) ,  YAMAGUCHI Ken (Office of the president, Shizuoka Cancer Center Hospital) ,  ANDO Takayuki (Shizuoka Institute of the Environment and Hygiene) ,  ISHIKAWA Yoshinobu (School of Pharmaceutical Sciences, University of Shizuoka) ,  ITO Mamoru (Central Institute for Experimental Animals) ,  AKIYAMA Yasuto (Immunotherapy Division, Shizuoka Cancer Center Research Institute)
Material： Biomedical Research (Web)
Volume： 40  Issue： 6  Page： 243-250(J-STAGE)  Publication year： 2019 
JST Material Number： U1102A  ISSN： 1880-313X  Document type： Article
Article type： 原著論文  Country of issue： Japan (JPN)  Language： ENGLISH (EN)

Thesaurus term： mouse(animal) ,...
Semi thesaurus term： NOG mouse ,...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=20A0444529&from=J-GLOBAL&jstjournalNo=U1102A") }}

JST classification (2)： Experimental treatment for tumors  (GE02040Y) ,  Basic research of antitumor(=antineoplastic)drugs  (GW16010A)

Substance index (1)： BMS-202

Reference (33)：

• 1 Abdel-Magid AF (2015) Inhibitors of the PD-1/PD-L1 pathway can mobilize the immune system: an innovative potential therapy for cancer and chronic infections. ACS Med Chem Lett 6, 489-490.
• 2 Akiyama Y, Nonomura C, Kondou R, Miyata H, Ashizawa T, Maeda C, Mitsuya K, Hayashi N, Nakasu Y and Yamaguchi K (2016) Immunological effects of the anti-programmed death-1 antibody on human peripheral blood mononuclear cells. Int J Oncol 49, 1099-1107.
• 3 Akiyama Y, Nonomura C, Ashizawa T, Iizuka A, Kondou R, Miyata H, Sugino T, Mitsuya K, Hayashi N, Nakasu Y, et al. (2017) The anti-tumor activity of the STAT3 inhibitor STX0119 occurs via promotion of tumor-infiltrating lymphocyte accumulation in temozolomide-resistant glioblastoma cell line. Immunol Lett 190, 20-25.
• 4 Ashizawa T, Iizuka A, Nonomura C, Kondou R, Maeda C, Miyata H, Sugino T, Mitsuya K, Hayashi N, Nakasu et al. (2017) Antitumor effect of programmed death-1 (PD-1) blockade in humanized the NOG-MHC double knockout mouse. Clin Cancer Res 23, 149-158.
• 5 Basu S, Yang J, Xu B, Magiera-Mularz K, Skalniak L, Musielak B, Kholodovych V, Holak TA and Hu L (2019) Design, synthesis, evaluation, and structural studies of C2-symmetric small molecule inhibitors of programmed cell death-1/programmed death-ligand 1 protein-protein interaction. J Med Chem 62, 7250-7263.

Terms in the title (8)： MHC ,  ノックアウト ,  NOGマウス ,  PD-1 ,  PD-L1 ,  阻害剤 ,  BMS ,  抗腫瘍活性